<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02930005</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-15-0329</org_study_id>
    <nct_id>NCT02930005</nct_id>
  </id_info>
  <brief_title>Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders</brief_title>
  <official_title>A Pilot Open-label Trial of Pentosan Polysulfate Sodium and Meclofenamic Acid As Adjunctive Treatments in Patients With Psychotic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the feasibility of administering meclofenamic acid or pentosan
      polysulfate sodium as an adjunctive treatment to patients diagnosed with a psychotic
      disorder. Half of participants will receive meclofenamic acid, while the other half will
      receive polysulfate sodium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic, low-grade brain inflammation is involved in the development of schizophrenia and
      other psychotic disorders. Medications with anti-inflammatory properties, like meclofenamic
      acid and pentosan polysulfate may help to reduce brain inflammation and serve as a treatment
      of psychotic disorders.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">November 4, 2017</completion_date>
  <primary_completion_date type="Actual">November 4, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cognitive function</measure>
    <time_frame>8 weeks</time_frame>
    <description>Improvement in scores on the NIH Toolbox cognitive test battery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in severity of psychotic symptoms</measure>
    <time_frame>8 weeks</time_frame>
    <description>Reduction in the Positive and Negative Syndrome scores after 8 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Psychotic Disorders</condition>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Meclofenamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150mg meclofenamic acid daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentosan polysulfate sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg of pentosan polysulfate sodium daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meclofenamic acid</intervention_name>
    <arm_group_label>Meclofenamic acid</arm_group_label>
    <other_name>Meclomen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentosan polysulfate sodium</intervention_name>
    <arm_group_label>Pentosan polysulfate sodium</arm_group_label>
    <other_name>Elmiron</other_name>
    <other_name>Hemoclar</other_name>
    <other_name>Fibrase</other_name>
    <other_name>Anarthron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder,
             bipolar I disorder, delusional disorder, other specified schizophrenia spectrum and
             other psychotic disorders, unspecified schizophrenia spectrum and other psychotic
             disorders

          -  Negative pregnancy test in females of childbearing age

        Exclusion Criteria:

          -  Urine drug screen positive for psychostimulants such as cocaine, amphetamines and
             ecstasy

          -  Any infection, neoplasm, autoimmune disease or other primary inflammatory condition
             (3) Previous diagnosis of intellectual disability or dementia

          -  Current treatment with heparin

          -  Use of or allergy to non-steroidal anti-inflammatory agent or pentosan polysulfate
             sodium

          -  Current or anticipated corticosteroid use

          -  History of peptic ulcer disease, gastro esophageal reflux disease, or gastrointestinal
             bleeding

          -  Those on warfarin or any anticoagulant

          -  Current treatment with lithium or asthma medication

          -  Individuals with pre-existing liver, cardiac, or kidney disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Harris County Psychiatric Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Olaoluwa O Okusaga</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Psychotic</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizoaffective</keyword>
  <keyword>Bipolar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentosan Sulfuric Polyester</mesh_term>
    <mesh_term>Meclofenamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>December 4, 2017</submitted>
    <returned>January 2, 2018</returned>
    <submitted>February 7, 2018</submitted>
    <returned>March 6, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

